Psoriatic arthritis: novel targets add to a therapeutic renaissance
No Thumbnail Available
File version
Author(s)
Nash, Peter
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2018
Size
File type(s)
Location
License
Abstract
Psoriasis is the most common chronic autoinflammatory skin disease, affecting 2–3% of the world's population, of whom 10–30% have psoriatic arthritis. As a result of better elucidation of crucial pathogenic inflammatory pathways and the advent of biologic disease-modifying anti-rheumatic therapies, the treatment of psoriatic arthritis has undergone a renaissance.
Journal Title
Lancet
Conference Title
Book Title
Edition
Volume
391
Issue
10136
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Biomedical and clinical sciences
Clinical sciences
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
RESIDENT T-CELLS
Persistent link to this record
Citation
Nash, P, Psoriatic arthritis: novel targets add to a therapeutic renaissance, Lancet, 2018, 391 (10136), pp. 2187-2189